Silver Book Fact

An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease by $20 billion in 2020–from the expected $128 billion to $108 billion.

Alzheimer's Association. Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars. Washington, D.C.: Alzheimer’s Association; 2010. http://www.alz.org/documents_custom/trajectory.pdf

Reference

Title
Changing the Trajectory of Alzheimer’s Disease: How a treatment by 2025 saves lives and dollars
Publisher
Alzheimer’s Association
Publication Date
2010
Authors
Alzheimer's Association
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • If the progression of Parkinson’s disease were slowed by 50%, there would be a 35% reduction in excess costs.  
  • Stem Cell Therapy Study Shows Improved Motor Function in Parkinson’s
     
  • Studies have shown that active medical management of Alzheimer’s disease can significantly improve quality-of-life for the individual through all stages of the disease.  
  • A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.  
  • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.